Acurx Pharmaceuticals Inc. announced that the United States Patent and Trademark Office has granted a new U.S. patent, US 12,534,470, covering DNA Polymerase IIIC inhibitors. The patent includes compositions-of-matter, methods of use, and pharmaceutical compositions, further expanding the company’s intellectual property portfolio for its ACX-375C program. In addition to this latest U.S. patent, Acurx holds granted patents in Israel, Japan, India, and Australia, while additional applications are under review in other countries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief on February 02, 2026, and is solely responsible for the information contained therein.